Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Top economists call for ‘radical redirection’ focusing on healthcare

The WHO Economic Council’s new brief, Financing Health for All, points to three main actions: create fiscal space, direct investments, and the administration of public and private finance.

On public spending, the experts say that easing constraints imposed by outdated economic assumptions and reversing reforms that lead to big health care cuts, would allow spending to increase significantly.

According to the brief, investments to ensure equal access to healthcare for everyone, should become the central purpose of economic activity. Public leadership should work to create positive regulatory, taxation, and industrial policies, and boost investment in the field.

Finally, public and private finance should be governed by greater regulation of private health markets through measures that improve outcomes globally and on an equitable basis.

Source: UN News

https://news.un.org/en/story/2021/10/1104072

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!